SCHEMBL6397337

SCHEMBL6397337

CC(CC(O)c1c(O)cccc1OP(=O)(O)O)c1ccc(O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 1/20 0.38
INPP5B P32019 1/20 0.38
INPP5A Q14642 1/20 0.38
HTR2A P28223 2/20 0.35
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
NFKB1 P19838 2/20 0.32
NFKB2 Q00653 2/20 0.32
RELA Q04206 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
SRC P12931 3/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
GAA P10253 1/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
PDE3A Q14432 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ANPEP P15144 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397631 0.88 HIF1A (0.37) INPPL1INPP5BINPP5AHTR2ANFKB1
SCHEMBL6398355 0.85 ESR1 (0.34) INPPL1INPP5BINPP5AESR1ESR2
SCHEMBL7622367 0.82 INPPL1 (0.44) INPPL1INPP5BINPP5AHTR2AESR1
SCHEMBL6403291 0.81 ESR1 (0.36) ESR1ESR2NFKB1KDM4EALDH1A1
SCHEMBL6395881 0.81 INPPL1 (0.41) INPPL1INPP5BINPP5AHTR2AESR1
SCHEMBL6397106 0.81 INPPL1 (0.42) INPPL1INPP5BINPP5AHTR2ASRC
SCHEMBL6402761 0.79 ESR1 (0.44) INPPL1INPP5BINPP5AHTR2AESR1
SCHEMBL6397834 0.79 ESR1 (0.43) INPPL1INPP5BINPP5AHTR2AESR1
SCHEMBL6402717 0.78 ESR1 (0.34) ESR1ESR2KDM4EALDH1A1PTPN2
SCHEMBL6397995 0.78 HIF1A (0.36) INPPL1INPP5BINPP5AHTR2ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 INPPL1 85/4885INPP5B 137/4885INPP5A 190/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 INPPL1 82/4885INPP5B 116/4885INPP5A 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.